Literature DB >> 30343727

Abuse Potential of Biased Mu Opioid Receptor Agonists.

S Stevens Negus1, Kevin B Freeman2.   

Abstract

G protein-biased mu opioid receptor (GPB-MOR) agonists constitute an emerging class of opioid analgesics. The first-in-class GPB-MOR agonist TRV130 (oliceridine) produces typical opioid-like abuse-related effects in rodents and humans. Although GPB-MOR agonists may be safer than conventional opioids on some endpoints, prevailing evidence suggests that they will retain opioid-like abuse potential.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  abuse potential; bias; mu opioid receptor; reinforcement; reward

Mesh：

Substances：

Year:  2018        PMID： 30343727      PMCID： PMC8174448          DOI： 10.1016/j.tips.2018.08.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  20 in total

Review 1.  Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade.

Authors:  Thomas M Tzschentke
Journal:  Addict Biol       Date:  2007-09       Impact factor: 4.280

Review 2.  Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics.

Authors:  Edward R Siuda; Richard Carr; David H Rominger; Jonathan D Violin
Journal:  Curr Opin Pharmacol       Date:  2016-12-07       Impact factor: 5.547

3.  NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.

Authors:  Takahiro Miyazaki; Irene Y Choi; Werner Rubas; Neel K Anand; Cherie Ali; Juli Evans; Hema Gursahani; Marlene Hennessy; Grace Kim; Daniel McWeeney; Juergen Pfeiffer; Phi Quach; David Gauvin; Timothy A Riley; Jennifer A Riggs; Kathleen Gogas; Jonathan Zalevsky; Stephen K Doberstein
Journal:  J Pharmacol Exp Ther       Date:  2017-08-04       Impact factor: 4.030

4.  The Role of Science in Addressing the Opioid Crisis.

Authors:  Nora D Volkow; Francis S Collins
Journal:  N Engl J Med       Date:  2017-05-31       Impact factor: 91.245

5.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

Review 6.  Mu Opioid Pharmacology: 40 Years to the Promised Land.

Authors:  Gavril W Pasternak
Journal:  Adv Pharmacol       Date:  2017-11-15

7.  Structure-based discovery of opioid analgesics with reduced side effects.

Authors:  Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

8.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

9.  A nontoxic pain killer designed by modeling of pathological receptor conformations.

Authors:  V Spahn; G Del Vecchio; D Labuz; A Rodriguez-Gaztelumendi; N Massaly; J Temp; V Durmaz; P Sabri; M Reidelbach; H Machelska; M Weber; C Stein
Journal:  Science       Date:  2017-03-03       Impact factor: 47.728

Review 10.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492
View more
  16 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

Review 2.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

Review 3.  What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years?

Authors:  Michael Camilleri
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-28       Impact factor: 4.052

4.  Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.

Authors:  Nestor Nivardo Jiménez-Vargas; Yang Yu; Dane D Jensen; Diana Daeun Bok; Matthew Wisdom; Rocco Latorre; Cintya Lopez; Josue O Jaramillo-Polanco; Claudius Degro; Mabel Guzman-Rodriguez; Quentin Tsang; Zachary Snow; Brian L Schmidt; David E Reed; Alan Edward Lomax; Kara Gross Margolis; Christoph Stein; Nigel W Bunnett; Stephen J Vanner
Journal:  Gut       Date:  2021-03-30       Impact factor: 23.059

5.  TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects.

Authors:  Jérôme Busserolles; Ismail Ben Soussia; Laetitia Pouchol; Nicolas Marie; Mathieu Meleine; Maïly Devilliers; Céline Judon; Julien Schopp; Loïc Clémenceau; Laura Poupon; Eric Chapuy; Serge Richard; Florence Noble; Florian Lesage; Sylvie Ducki; Alain Eschalier; Stéphane Lolignier
Journal:  Br J Pharmacol       Date:  2020-09-21       Impact factor: 8.739

6.  Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone.

Authors:  Andrew J Kassick; Heather N Allen; Saigopalakrishna S Yerneni; Fathima Pary; Marina Kovaliov; Cooper Cheng; Marco Pravetoni; Nestor D Tomycz; Donald M Whiting; Toby L Nelson; Michael Feasel; Phil G Campbell; Benedict Kolber; Saadyah Averick
Journal:  ACS Appl Bio Mater       Date:  2019-07-25

7.  Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Authors:  Kathryn L Schwienteck; Kaycee E Faunce; Kenner C Rice; Samuel Obeng; Yan Zhang; Bruce E Blough; Travis W Grim; S Stevens Negus; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-01-18       Impact factor: 5.250

8.  Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein Activation Bias at the μ-Opioid Receptor.

Authors:  Rachel S Crowley; Andrew P Riley; Amy F Alder; Richard J Anderson; Dan Luo; Sophia Kaska; Pamela Maynez; Bronwyn M Kivell; Thomas E Prisinzano
Journal:  ACS Chem Neurosci       Date:  2020-05-26       Impact factor: 4.418

9.  Optimizing Perioperative Use of Opioids: A Multimodal Approach.

Authors:  Maria F Ramirez; Brinda B Kamdar; Juan P Cata
Journal:  Curr Anesthesiol Rep       Date:  2020-09-07

10.  In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.

Authors:  Jennifer M Bossert; Eugene A Kiyatkin; Hannah Korah; Jennifer K Hoots; Anum Afzal; David Perekopskiy; Shruthi Thomas; Ida Fredriksson; Bruce E Blough; S Stevens Negus; David H Epstein; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2020-02-24       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.